{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-168614","form_type":"8-K","ticker":"VRDN","cik":"0001590750","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2025-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.446342+00:00","generated_at":"2026-05-17T23:02:21.705274+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Viridian Therapeutics licenses veligrotug, VRDN-003 to Kissei for Japan; $70M upfront, up to $315M milestones","bullets":["Upfront payment of $70M; up to $315M in development, regulatory, and commercial milestones.","Tiered royalties on Japan net sales in the 20s to mid-30s percent range.","Kissei gets exclusive Japan rights; Viridian retains manufacturing/supply responsibilities except limited cases.","Veligrotug (VRDN-001) and VRDN-003 are anti-IGF-1R antibodies targeting thyroid eye disease.","THRIVE and THRIVE-2 phase 3 trials for veligrotug met all primary and secondary endpoints."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-168614","json":"https://secwatch.observer/filing/0001193125-25-168614.json","markdown":"https://secwatch.observer/filing/0001193125-25-168614.md","text":"https://secwatch.observer/filing/0001193125-25-168614.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590750/000119312525168614/0001193125-25-168614-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590750/000119312525168614/d24708d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T23:02:21.705274+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}